Loading...

Ambea

DB:6MA
Snowflake Description

High growth potential with proven track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6MA
DB
SEK6B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Ambea AB (publ), through its subsidiaries, primarily provides residential care services for people with disabilities and elderly care in Sweden and Norway. The last earnings update was 10 days ago. More info.


Add to Portfolio Compare Print
6MA Share Price and Events
7 Day Returns
1%
DB:6MA
3.5%
DE Healthcare
1.2%
DE Market
1 Year Returns
-
DB:6MA
-21.3%
DE Healthcare
-11.2%
DE Market
6MA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Ambea (6MA) 1% -7.9% -4.5% - - -
DE Healthcare 3.5% 13.3% 1% -21.3% -15.5% 33.6%
DE Market 1.2% 2.7% 1.7% -11.2% 12% 6.1%
1 Year Return vs Industry and Market
  • No trading data on 6MA.
  • No trading data on 6MA.
Price Volatility
Industry
5yr Volatility vs Market

6MA Value

 Is Ambea undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Ambea to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data    Our calculation method for this is changing soon.

Below are the data sources, inputs and calculation used to determine the intrinsic value for Ambea.

DB:6MA Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:6MA
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 9.8%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.68
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.683 (1 + (1- 22%) (35.5%))
0.872
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.87
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.872 * 9.77%)
8.75%

Discounted Cash Flow Calculation for DB:6MA using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Ambea is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:6MA DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (SEK, Millions) -1,583.50 515.00 725.25 793.92 869.10
Source Analyst x4 Analyst x4 Analyst x4 Est @ 9.47% Est @ 9.47%
Present Value
Discounted (@ 8.75%)
-1,456.08 435.45 563.89 567.61 571.35
Present value of next 5 years cash flows SEK682.22
DB:6MA DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= SEK869.10 × (1 + 0.23%) ÷ (8.75% – 0.23%)
SEK10,220.61
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= SEK10,220.61 ÷ (1 + 8.75%)5
SEK6,719.17
DB:6MA Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= SEK682.22 + SEK6,719.17
SEK7,401.39
Equity Value per Share
(SEK)
= Total value / Shares Outstanding
= SEK7,401.39 / 67.55
SEK10.01
DB:6MA Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:6MA represents 0.09138x of OM:AMBEA
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.09138x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (SEK) x Listing Adjustment Factor
= SEK 109.56 x 0.09138
€10.01
Value per share (EUR) From above. €10.01
Current discount Discount to share price of €7.83
= -1 x (€7.83 - €10.01) / €10.01
21.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Ambea is available for.
Intrinsic value
22%
Share price is €7.83 vs Future cash flow value of €10.01
Current Discount Checks
For Ambea to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Ambea's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Ambea's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Ambea's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Ambea's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:6MA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in SEK SEK4.37
OM:AMBEA Share Price ** OM (2019-02-22) in SEK SEK85.7
Germany Healthcare Industry PE Ratio Median Figure of 10 Publicly-Listed Healthcare Companies 21.59x
Germany Market PE Ratio Median Figure of 420 Publicly-Listed Companies 18.04x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Ambea.

DB:6MA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:AMBEA Share Price ÷ EPS (both in SEK)

= 85.7 ÷ 4.37

19.62x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ambea is good value based on earnings compared to the DE Healthcare industry average.
  • Ambea is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Ambea's expected growth come at a high price?
Raw Data
DB:6MA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 19.62x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
27.8%per year
Germany Healthcare Industry PEG Ratio Median Figure of 7 Publicly-Listed Healthcare Companies 1.23x
Germany Market PEG Ratio Median Figure of 277 Publicly-Listed Companies 1.4x

*Line of best fit is calculated by linear regression .

DB:6MA PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 19.62x ÷ 27.8%

0.71x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ambea is good value based on expected growth next year.
Price based on value of assets
What value do investors place on Ambea's assets?
Raw Data
DB:6MA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in SEK SEK40.08
OM:AMBEA Share Price * OM (2019-02-22) in SEK SEK85.7
Germany Healthcare Industry PB Ratio Median Figure of 12 Publicly-Listed Healthcare Companies 1.48x
Germany Market PB Ratio Median Figure of 565 Publicly-Listed Companies 1.78x
DB:6MA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:AMBEA Share Price ÷ Book Value per Share (both in SEK)

= 85.7 ÷ 40.08

2.14x

* Primary Listing of Ambea.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ambea is overvalued based on assets compared to the DE Healthcare industry average.
X
Value checks
We assess Ambea's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Ambea has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

6MA Future Performance

 How is Ambea expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
27.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Ambea expected to grow at an attractive rate?
  • Ambea's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Ambea's earnings growth is expected to exceed the Germany market average.
  • Ambea's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:6MA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:6MA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 27.8%
DB:6MA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 20.5%
Germany Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 2.3%
Germany Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 5.3%
Germany Market Earnings Growth Rate Market Cap Weighted Average 10%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:6MA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:6MA Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 12,748 988 655 4
2020-12-31 12,019 896 573 4
2019-12-31 10,725 549 351 4
DB:6MA Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2018-12-31 6,076 538 295
2018-09-30 5,990 532 317
2018-06-30 5,937 543 307
2018-03-31 5,860 382 253
2017-12-31 5,816 342 226
2017-09-30 5,763 291 178
2017-06-30 5,651 281 148
2017-03-31 5,561 265 139
2016-12-31 5,335 210 128

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Ambea's earnings are expected to grow significantly at over 20% yearly.
  • Ambea's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:6MA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Ambea Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6MA Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 7.91 8.43 7.39 4.00
2020-12-31 6.91 7.72 6.17 4.00
2019-12-31 4.56 5.76 4.07 4.00
DB:6MA Past Financials Data
Date (Data in SEK Millions) EPS *
2018-12-31 4.37
2018-09-30 4.69
2018-06-30 4.54
2018-03-31 3.74
2017-12-31 3.38
2017-09-30 2.69
2017-06-30 2.26
2017-03-31 2.14
2016-12-31 1.97

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Ambea is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Ambea's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Ambea has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

6MA Past Performance

  How has Ambea performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Ambea's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Ambea has delivered over 20% year on year earnings growth in the past 5 years.
  • Ambea's 1-year earnings growth is less than its 5-year average (30.5% vs 44%)
  • Ambea's earnings growth has exceeded the DE Healthcare industry average in the past year (30.5% vs 12.5%).
Earnings and Revenue History
Ambea's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Ambea Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6MA Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 6,076.00 295.00 1,217.00
2018-09-30 5,990.00 317.00 1,193.00
2018-06-30 5,937.00 307.00 1,174.00
2018-03-31 5,860.00 253.00 1,108.00
2017-12-31 5,816.00 226.00 1,105.00
2017-09-30 5,763.00 178.00 1,151.00
2017-06-30 5,651.00 148.00 1,122.00
2017-03-31 5,561.00 139.00 1,108.00
2016-12-31 5,335.00 128.00 1,008.00
2015-12-31 4,350.00 3.00 698.00
2014-12-31 4,165.00 46.00 656.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Ambea has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Ambea used its assets more efficiently than the DE Healthcare industry average last year based on Return on Assets.
  • Ambea has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Ambea's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Ambea has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

6MA Health

 How is Ambea's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Ambea's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Ambea's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Ambea's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Ambea's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Ambea Company Filings, last reported 1 month ago.

DB:6MA Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 2,707.00 2,055.00 62.00
2018-09-30 2,684.00 2,233.00 80.00
2018-06-30 2,556.00 2,273.00 80.00
2018-03-31 2,544.00 2,123.00 77.00
2017-12-31 2,480.00 2,102.00 87.00
2017-09-30 2,435.00 2,498.00 471.00
2017-06-30 2,316.00 2,444.00 496.00
2017-03-31 2,101.00 2,427.00 427.00
2016-12-31 2,067.00 2,321.00 318.00
2015-12-31 1,933.00 923.00 189.00
2014-12-31 1,764.00 813.00 55.00
  • Ambea's level of debt (75.9%) compared to net worth is high (greater than 40%).
  • Unable to establish if Ambea's debt level has increased without past 5-year debt data.
  • Debt is well covered by operating cash flow (26.2%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 12.3x coverage).
X
Financial health checks
We assess Ambea's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Ambea has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

6MA Dividends

 What is Ambea's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.28%
Current annual income from Ambea dividends. Estimated to be 2.25% next year.
If you bought €2,000 of Ambea shares you are expected to receive €26 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Ambea's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.54%).
  • Ambea's dividend is below the markets top 25% of dividend payers in Germany (3.93%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:6MA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Germany Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 1.6%
Germany Market Average Dividend Yield Market Cap Weighted Average of 332 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:6MA Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 2.37 4.00
2020-12-31 2.07 4.00
2019-12-31 1.36 4.00
DB:6MA Past Annualized Dividends Data
Date (Data in SEK) Dividend per share (annual) Avg. Yield (%)
2019-02-13 1.100 1.312
2018-04-17 1.000 1.291

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • It is too early to tell whether Ambea has stable dividend payments.
  • Ambea only just started paying a dividend, it is too early to tell if payments are increasing.
Current Payout to shareholders
What portion of Ambea's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (4x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (3.8x coverage).
X
Income/ dividend checks
We assess Ambea's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Ambea afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Ambea has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

6MA Management

 What is the CEO of Ambea's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Fredrik Gren
COMPENSATION SEK5,434,983
AGE 50
TENURE AS CEO 7 years
CEO Bio

Mr. Fredrik Gren serves as the Chief Executive Officer and President of Ambea AB (Ambea) at Carema Care AB since February 1, 2012. Mr. Gren served as President of Ambea AB. He served as the Chief Executive Officer of Menigo Foodservice AB. Mr. Gren began his career at McKinsey & Company, where he spent nine years and was its Partner. He served as the Chief Financial Officer of Sveriges Television from 2002 to 2006. He served as Chief Financial Officer of Menigo Foodservice since 2006. He served as Chairman of the Board of Mehiläinen Oy. Mr. Gren serves as an Executive Director of Menigo Foodservice AB. Mr. Gren has been a Director of Ambea AB since 2012. He holds an M.Sc from the Stockholm School of Economics in the year 1990 to 1993 and MBA Exchange program from UCLA Anderson School of Management in 1993.

CEO Compensation
  • Fredrik's compensation has been consistent with company performance over the past year.
  • Fredrik's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Ambea management team in years:

6.1
Average Tenure
59
Average Age
  • The average tenure for the Ambea management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Fredrik Gren

TITLE
CEO, President & Director
COMPENSATION
SEK5M
AGE
50
TENURE
7 yrs

Daniel Warnholtz

TITLE
Deputy CEO & CFO
AGE
45
TENURE
8.1 yrs

Jacob Persson

TITLE
Head of Investor Relations
TENURE
0.7 yrs

Margareta Sööder

TITLE
Director of Human Resources
AGE
62

Agneta Lindgren

TITLE
Temporary Head of Nytida
AGE
61
TENURE
2.2 yrs

Ulla Tansen

TITLE
Business Area Head of Vardaga
AGE
59
TENURE
6.1 yrs

Lena Freiholtz

TITLE
Head of Quality
AGE
63

Eva Domanders

TITLE
Chief Executive Officer of Klara
AGE
52
Board of Directors Tenure

Average tenure and age of the Ambea board of directors in years:

3.6
Average Tenure
56
Average Age
  • The tenure for the Ambea board of directors is about average.
Board of Directors

Lena Hofsberger

TITLE
Chairperson
COMPENSATION
SEK898K
AGE
64
TENURE
6.1 yrs

Fredrik Gren

TITLE
CEO, President & Director
COMPENSATION
SEK5M
AGE
50
TENURE
7 yrs

Gunilla Rudebjer

TITLE
Director
COMPENSATION
SEK387K
AGE
59
TENURE
2.5 yrs

Ingrid Blank

TITLE
Director
COMPENSATION
SEK385K
AGE
56
TENURE
7.1 yrs

Anders Bengt Borg

TITLE
Director
COMPENSATION
SEK378K
AGE
42
TENURE
5.1 yrs

Thomas Hofvenstam

TITLE
Director
COMPENSATION
SEK340K
AGE
49
TENURE
4.1 yrs

Patricia Rodriguez

TITLE
Employee Representative Director
TENURE
3.1 yrs

Haralampos Kalpakas

TITLE
Employee Representative Director
TENURE
3.1 yrs

Magnus Sällström

TITLE
Employee Representative Director
TENURE
3.1 yrs

Lars Gatenbeck

TITLE
Director
AGE
62
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Ambea's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Ambea has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

6MA News

Simply Wall St News

6MA Company Info

Map
Description

Ambea AB (publ), through its subsidiaries, primarily provides residential care services for people with disabilities and elderly care in Sweden and Norway. The company operates through Vardaga, Nytida, and Other: Norway and Staffing Solutions segments. It offers services for the short-term stays outside of the home, group homes or residential facilities, and with special service and daily activities for adults with an autism diagnosis and brain damage or other intellectual disabilities; and support services in the form of HVB homes, assisted housing, family homes, outpatient care, special housing, and inpatient care for children, young people, and adults and families under the Nytida brand, as well as special housing services for the elderly, such as older people, who are unable to remain in their own homes and require support to maintain their independence in a safe living environment under the Vardaga brand. The company also provides training and staffing solutions for municipalities, county councils, and private operators under the Klara brand; and works with the temporary supply and recruitment of doctors and nurses, as well as offers residential and outpatient psychiatric support, and residential facilities for people with lifelong disabilities under the Heimta brand. In addition, it offers ambulatory services. Ambea AB (publ) was founded in 1996 and is headquartered in Solna, Sweden. Ambea AB (publ) is a subsidiary of Actor S.C.A.

Details
Name: Ambea AB (publ)
6MA
Exchange: DB
Founded: 1996
SEK546,023,948
67,554,279
Website: http://www.ambea.com
Address: Ambea AB (publ)
Evenemangsgatan 21, 6 tr,
Box 1565,
Solna,
Stockholm County, 171 29,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM AMBEA Ordinary Shares OMX Nordic Exchange Stockholm SE SEK 31. Mar 2017
DB 6MA Ordinary Shares Deutsche Boerse AG DE EUR 31. Mar 2017
LSE 0RNX Ordinary Shares London Stock Exchange GB SEK 31. Mar 2017
BATS-CHIXE AMBEAS Ordinary Shares BATS 'Chi-X Europe' GB SEK 31. Mar 2017
Number of employees
Current staff
Staff numbers
26,000
Ambea employees.
Industry
Health Care Facilities
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/02/23 23:21
End of day share price update: 2019/02/22 00:00
Last estimates confirmation: 2019/02/20
Last earnings filing: 2019/02/13
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.